| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7c6f35eb968c4fb96f0f0b8fa6b4ddc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate |
2017-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfbbeefafd0a9e1f13ab7faa74e9ad71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_303c642d6ce2aa54d6bec97e07527032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9591d565bcabce54e691a470f703b90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7b22aa3c69ccbb40a20c1c844aa2ed0 |
| publicationDate |
2019-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112019011410-A2 |
| titleOfInvention |
methods for treating a patient having cancer, for increasing a proinflammatory immune effector cell population, for increasing the level of t-cell activation, for reducing the population of regulatory t-cells, for inhibiting the immunosuppressive function of regulatory t-cells, for the long-term enhancement of tumor-specific memory t-cell generation and to protect intratumoral immune cells from chemotherapy. |
| abstract |
The addition of a fast acting short-acting selective cdk 4/6 inhibitor in a very specific dosing regimen for the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected finding is that specifically timed short pulsatile administration of a CDK 4/6 fast-acting short-half selective inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancerous microenvironment. . |
| priorityDate |
2016-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |